13 March 2017:
OPTRONICS® Announces the Release of OcularCINEMA™ 4K.
OPTRONICS a leading developer of high definition microscope camera systems for clinical, research and industrial microscopy announced the release of their all-new OcularCINEMA 4K progressive scan remote head c-mount camera system for research and industrial microscope visualization applications.
The OcularCINEMATM 4K 3 CMOS Ultra HD color microscope camera package delivers a true progressive scan real-time view of the ocular viewing experience to the largest displays and projectors with 4X the resolution of standard HD video. The package enables effortless connection to a compound microscope with an included adapter compatible for most OLYMPUS® , LEICA® and NIKON® microscopes.
"Our new line of OcularCINEMA 4K camera packages further enhance our portfolio of imaging solutions, providing our customers with greater options to fit their evolving application areas and budget requirements while continuing our promise and tradition of delivering an incredible immersive imaging experience from our customers microscopes" said Mike Drabik, National Sales Manager at OPTRONICS. "This was more evident than ever this week at the USCAP meeting in San Antonio Texas, where the camera was unveiled." Mr. Drabik added.
To learn more about OcularCINEMA 4K and other exciting new microscope imaging innovations visit optronics.com.
9 March 2017:
IncellDx Launches OncoTect® iO® Quantitative, Single Cell PD-L1 Assay at USCAP Meeting in San Antonio, TX
IncellDx, Inc. announces the release of the OncoTect iO Quantitative, Single Cell PD-L1 Assay, for research use only. The test kit includes labeled antibodies to PD-L1 and CD45, CD8, CD3 cell subsets plus a DNA dye for cell cycle and quantitative detection of PD-L1 expression in non-small cell lung cancer tissue (NSCLC). Single cell preparations from tumor tissue are first prepared using IncellPREP (IVD) Single Cell Tissue Kit then processed using the OncoTect iO® kit. PD-L1 is quantified on immune and tumor cells, including tumor cells in different phases of the cell cycle, using flow cytometry. This quantitative methodology offers highly reproducible results and expanded information as compared to current methods.
For more information, please visit www.incelldx.com. Contact IncellDx, Inc., Chris Meda at +1-650-777-7630
9 February 2017:
Bio SB Announces 25 New IVD Biomarkers for Immunohistochemistry
Among the new products we are launching, is a new line of unique reagents for Mesothelioma diagnosis, including BAP1, Mesothelial Cell HBME 1, and Caveolin 1. In 2017, Bio SB is has made a commitment to lead the way in providing IVD reagents used for Alzheimer & Parkinson disease diagnosis. The first step in this commitment is the launch of 3 new antibodies, Alpha Synuclein, Amyloid Beta, and Tau, all used in the diagnosis of Alzheimer and Parkinson disease. Additionally we continue to add unique Rabbit Monoclonal antibodies to our portfolio like CD16, CD33, GATA3, HE4, Inhibin alpha, LAG-3, Langerin, LEF-1, Parvalbumin, SMAD4 and STAT6.
For more information please visit: http://www.biosb.com/newproducts/
5 December 2016:
CloudLIMS introduces version 1.58 of CloudLIMS Lite, a cloud based LIMS offered as SaaS. The new
version allows batch processing of data, inventory tracking, kit management and centralized single click
operations coupled with an intuitive interface.
CloudLIMS Lite helps biobanks, clinical, research, diagnostic and testing laboratories to seamlessly manage their data, right from sample accessioning to generating custom reports. CloudLIMS Lite eliminates the need to invest in IT infrastructure. The hosting is complimentary, data backups are automatic, upgrades are current, all at an assured 99.5% up time. Automate workflows quickly, using this secure and scalable product.
For more information, please visit: https://www.cloudlims.com/lims-products/lims-and-sample-management.html
31 October 2016:
Roche announces FDA approval for VENTANA PD-L1 (SP142) Assay to support immunotherapy treatment decisions in lung cancer
First FDA-approved test to support patient treatment decisions for TECENTRIQ (atezolizumab) in non-small cell lung cancer
Roche announced approval of the VENTANA PD-L1 (SP142) Assay by the U.S. Food and Drug Administration (FDA) as a complementary diagnostic to identify PD-L1 expression levels in patients considering treatment with the FDA-approved Roche cancer immunotherapy TECENTRIQ® (atezolizumab) for previously treated metastatic non-small cell lung cancer (NSCLC). The PD-L1 (SP142) assay is also indicated to identify patients with urothelial cancer (UC) who may benefit from treatment with TECENTRIQ.
This innovative biomarker assay is the first to evaluate patient PD-L1 expression using both tumor cell and immune cell staining. Determining a patient's PD-L1 expression level can provide insight into the survival benefit that may be achieved from treatment with TECENTRIQ.
The VENTANA PD-L1 (SP142) Assay can now be performed on the VENTANA BenchMark ULTRA automated tissue staining instrument. With an established presence in laboratories globally, availability of the assay on the VENTANA BenchMark ULTRA instrument can provide broader access for patients and decrease the time spent waiting for PD-L1 test results.
Roche will continue to pursue regulatory approval for the VENTANA PD-L1 (SP142) Assay in combination with TECENTRIQ in other cancer indications and in other geographies. For more information, go to PDL1ihc.com.
10 October 2016:
Kapios Health Introduces Assured Compliance Solution
Never miss a scheduled maintenance event or get surprised by a performance test with Kapios Health's Assured Compliance Solution (ACS™). ACS™ replaces cumbersome papers and notebooks with one mobile device to boost the productivity of lab engineers and technicians and help maintain the integrity of the documentation. ACS™ is a secure, centralized database for users to record and review equipment status, access historical records, and run reports, all in real-time. If a scheduled activity is not logged as completed, ACS™ triggers a chain of alerts until the task is addressed.
For additional information, visit our website and request a free demo.
8 August 2016: Bio SB Announces New Non-Toxic and Solvent-Free Environmentally Friendly Ancillaries for IHC and ISH.
Bio SB is pleased to announce a new line of Non-Toxic and Solvent-Free, Environmentally Friendly Ancillaries for use in Histology, Immunohistochemistry (IHC), Immunocytochemistry (ICC) and in situ Hybridization (CISH & FISH) applications.
Introducing TintoDeparaffinator Citrate, TintoDeparaffinator EDTA, ChromoProtector and XyGreen PermaMounter:
When IHC, ICC, CISH and FISH procedures are performed using the Bio SB TintoDeparaffinator Citrate or EDTA to deparaffinize, rehydrate and retrieve FFPE tissues, the ChromoProtector to preserve stains, and the XyGreen PermaMounter for mounting tissues, they allow for a solvent-free environment when conducting histological, immunohistochemical and in situ hybridization procedures.
The new TintoDeparaffinator Citrate and EDTA provide safe, efficient and economical alternatives to traditional tissue deparaffinization. These solvent free ancillaries are non- toxic, biodegradable and a great solution for labs handling FFPE tissues that would like to reduce exposure to toxic solvents like xylene, toluene and alcohols. The new ChromoProtector helps to dissolve micro-paraffin leftovers and preserve stains of substrate-chromogens that are dissolved or sensitive to fading, like AEC, Fast Red, HRP Blue, HRP Green, ALK Magenta, ALK Scarlet, ALK Red and ALK Brown, when mounted with solvent-based permanent mounting media. The Bio SB ChromoProtector is also suitable to mount substrate-chromogens such as DAB, HRP Black, ALK Blue or others that are resistant to solvents. The XyGreen PermaMounter is a solvent free, non-toxic and biodegradable permanent mounting media that allows permanent mounting of tissues for molecular pathology applications.
For more information call 805-692-2768, email [email protected] or visit http://www.biosb.com.
5 August 2016: FAQs about the Pathology Recertification Exam
Are you preparing for your American Board of Pathology (ABPATH) MOC exam? Here's a guide to help you navigate through the process. This exam is designed to provide physicians with the appropriate standards to maintain quality care throughout their career.
The Pathology Recertification exam is generally considered to be easier than the initial certification. However, don't think that you'll breeze through without properly preparing. It is important to plan on studying for at least a month to properly prepare. (You may also need to plan for additional study time depending on which sub-specialty you choose). The exam is administered 2 times a year - in spring (March) and fall (August).
Click here for more information.
1 August 2016: Evidence-based and Online Educational Resource at the Point of Need for Pathologists and Medical Laboratory Professionals
ASCP has launched a NEW, evidence-based, online diagnostic (Dx) toolkit that provides educational resources at the point of need to enhance your understanding of the diagnosis and management of breast cancer.
Every resource is organized to seamlessly integrate with the laboratory work flow:
- Tumor sampling
- Sample processing and transportation
- Testing and image analysis
- Scoring and interpretation
- Reporting and clinician communication
This Dx Toolkit resource is refreshed on a regular basis with the latest evidence-based, actionable research identified by ASCP subject matter experts to enhance Cancer diagnosis.
The Dx Toolkit leverages resources from ASCP's expansive library:
- Peer-reviewed multimedia courses
- Academic journals
- Enduring materials
- Referential content
- Case of the Month series
Every resource is organized to seamlessly integrate with the laboratory work flow.
Unique to all cancer diagnostic education is that knowledge resources have a short shelf life. This online site is refreshed on a regular basis with evidence-based research identified by ASCP subject matter experts.
Enhance your understanding of diagnosis and management of breast cancer. Register Now.
25 July 2016:
VENTANA PD-L1 (SP142) Assay
Using the right test to determine PD-L1 status for immunotherapy options is important, and the VENTANA PD-L1 (SP142) Assay is the first and only FDA-approved test predictive for TECENTRIQ™ in urothelial carcinoma (UC) patients.
- FDA-approved to predict UC patient response to TECENTRIQ™
- Designed to enhance visual contrast of immune cell staining within the tumor microenvironment
- Stains PD-L1 in both tumor cells (TC) and tumor-infiltrating immune cells (IC)
Find a testing site.
25 July 2016:
Mopec Introduces Fully Submersible Oscillating Autopsy Saw
'Mopec Autopsy Saw 5000 is lighter, quieter with an ergonomic shape'
Mopec brings a safer more efficient solution to autopsy technology with the introduction of the Mopec Autopsy Saw 5000 - a fully submersible oscillating autopsy saw with an innovative blade design. Weighing less than three pounds, the Mopec Autopsy Saw 5000 is approximately one pound lighter than previous market options. Placement of the motor in the head and handle of the unit provides a balanced weight - resulting in a more precise cut with less operator fatigue.
Packaged with a total of four, non-corrosive, chrome plated steel blades in 64 mm and 76 mm circular and 51 mm and 64 mm segmented; the blade range supports all autopsy requirements. Designed for strength and effectiveness; course teeth enhance the cutting edge and reduce blockage. Oscillating at 13,200 cycles per minute, blade strength and durability allows for a five-year minimum life span with recommended annual maintenance. Changing blades is quick and easy with Mopec's included unique blade clamp and blades can be rotated four times; surpassing the current industry standard of three.
Compact with lightweight construction, the new saw is easily portable, or can be securely built into any autopsy table. Specifically designed for autopsies, the Mopec 5000 is FDA listed and has CE certification.
For laboratories looking for the convenience of a bone vacuum, the saw works in conjunction with the optional Mopec Bone Vacuum 5000. Compact, portable and capable of extracting all harmful debris and matter, the vacuum rests on four large casters - all with brakes. With a bag capacity of 7-liters, the vacuum is IP44 water resistant and has 3-stage filtration, a HEPA filter, a cloth filter and paper filter bag.
For more information visit: www.mopec.com.